Video

ASCRS Live: Pipeline update from Johnson and Johnson

Sandor Palfi, Commercial Vice President of the Americas at Johnson & Johnson Vision discussed pipeline updates for the company including the ELITA femtosecond platform at the 2023 ASCRS annual meeting in San Diego.

Sandor Palfi, Commercial Vice President of the Americas at Johnson & Johnson Vision discussed pipeline updates for the company including the ELITA femtosecond platform at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Sandor Palfi:

Hello, I'm Sandor Palfi, vice president of the Americas, Surgical Vision, for Johnson and Johnson Vision. We're here in San Diego, which is actually only an hour drive away from my house and from my home and the home of Johnson and Johnson Vision as well in Irvine. So, we're super, super excited to be here to represent the best of what we have to bring to customers and to patients. Because we do care and that's what we are really passionate about is the outcomes that we deliver to patients every single day.

Now, Johnson and Johnson Vision is entering into a new phase. We are fueled by the largest healthcare company in the world. We are redefining how we look at the patient journey from the pediatric eye to the aging eye. When you look at our booth, we are truly focused on and double down on what are the exciting products and innovations we've been both in cataract and as well as in refractive.

This time I'm going to start with our refractive innovations. We are unveiling ELITA, which is our new femtosecond platform and is going to do a great flap for every single patient. It's an outstanding system that we just got 510(k) FDA approval a week ago. On the cataract side, we have also a great portfolio of PCIOLs that we are bringing here, and as well as our latest and greatest new innovation of the Veritas phaco platform.

Last, but not least, are other areas that we are super proud of and we are as passionate about as product innovation. One of them is our publication presence. We are bringing 43 new publications to the symposium to represent the outcomes that our products bring to customers and to patients.

And as well as another area which we really focus is how we can become better at championing causes for diversity, equity, and inclusion. I was actually just coming out from our diversity, equity, and inclusion meeting with some of the great key opinion leaders. We were discussing how we as an industry, together with ophthalmologists can advance this cause further even. We're looking forward to a great meeting, continuing to work together with our colleagues here with the ophthalmologists and with the industry to better advance healthcare and have sight for life. Thank you.

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
© 2024 MJH Life Sciences

All rights reserved.